From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC ...

Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, ...

Disease progression over time for Parkinson's In the very earliest stages of Parkinson’s, one of the most common symptoms is REM sleep behaviour disorder, in which the person acts out their dreams ...

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or ...

A loss of the sense of smell or acting out one’s dreams can occur years in advance.

According to recent data from medical records, Nebraska and Kansas have the highest rates of Parkinson’s disease diagnoses.